Bergen Brunswig (NYSE: BBC) signed a stock purchase agreement to acquire Stadtlander Drug Co., wholly owned subsidiary of Counsel Corp. (Nasdaq: CXSNF) for approximately $400 million. Part of the deal gives Bergen the right to vote Counsel's shares of PharMerica, Inc. (Nasdaq: DOSE) (about 9% of outstanding DOSE shares) under certain circumstances. For complete details, click "news" above.
Does anyone see the combination of this deal and DOSE's hiring of DLJ as the prelude to a sale?Also, while I expected growth turbulence, the latest news is the first I've heard regarding the poor performance of the 5 pharmacies and the troubles with customer payments. While my basis is low, I wonder if those investors who bought in the teens are thinking "lawsuit"?Looking for better news,kjs1
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |